The Oxygen Problem: Why Some Investments Fail Before They Begin

In 2014, I began studying the stock market seriously. Over the years that followed, I reviewed hundreds of companies, both listed and private. A pattern emerged that most investors overlook.

Cash flow acts as the oxygen of a business. Investment capital works like a ventilator, keeping the company breathing until it can stand on its own. The trouble starts when the ventilator gets removed too early.

The clock that never matches

Public market investors and venture capitalists both operate on a clock. They commit money with an expectation that it will multiply within a set window. That window rarely matches the company's actual growth timeline. So the money often gets pulled at the exact moment the business needs it most. I call this the oxygen problem.

A company under this pressure looks strong on paper right up until the funding dries up. Then the weaknesses that were always there become visible to everyone.

Both sides of the table

It is tempting to blame one side for this outcome. But the truth sits on both sides of the table. Sometimes the promoter overpromises to secure the round. Sometimes the investor pushes for returns faster than the business model allows. Greed shows up in both forms and both are costly.

Consider a case I studied closely, a mid-sized manufacturing company I will call Company A. Company A raised a Series B round on the promise of doubling revenue within eighteen months. The promoter believed in the number and pitched it with total confidence. The investors signed off because the market comparisons looked favorable at the time.

Eighteen months later, revenue had grown, but only by forty percent. The investors, bound by their own fund timelines, began pressing for an exit. Company A needed another eighteen months of working capital to reach the promised scale. Instead, it got a forced restructuring and a change in leadership. The product was solid, the market was real, but the timeline mismatch broke the company.

This is not a rare story. It repeats across sectors and geographies. I have seen it in retail, in logistics, in software, and in healthcare. The specific numbers change, but the structure of the failure stays the same.

When two schedules collide

Investors want liquidity on a schedule. Businesses grow on their own schedule, shaped by customers, supply chains, and market conditions. When those two schedules collide, someone has to give way. Usually it is the business that gives way, because the investor holds the leverage.

Due diligence goes both ways

Most founders think due diligence is something investors do to them. Few founders do equal diligence on the investors sitting across the table.

• A founder should ask how long the fund has before it must return capital to its own backers.
• A founder should ask what the fund did with its last three portfolio companies during a downturn.

These questions reveal more about the working relationship than any pitch deck ever will.

On the other side, investors owe founders the same clarity. An investor should be honest about the timeline pressure they carry from their own limited partners. An investor should explain what happens if growth targets are missed by a reasonable margin. Hiding this pressure until year three helps no one.

What the best partnerships share

The best partnerships I have studied share one trait. The founder can describe a ten-year vision in plain language, without hiding behind buzzwords. The investor treats that vision as something to build with, not just a number to track. When that alignment exists, both sides adjust their expectations as the business evolves. When it does not exist, both sides quietly wait for the other to fail first.

A different path

I watched a second company, which I will call Company B, take a different path. Company B needed capital to expand its distribution network. Instead of raising equity, the promoter took a structured loan against future receivables. The interest rate was higher than a typical bank loan. But the promoter kept full control over the pace of expansion. There was no board pressure to hit an arbitrary revenue number by a fixed date.

The company grew slower than a VC-backed competitor in the same space. Three years later, the competitor had folded after a funding round fell through. Company B was still standing, profitable, and debt-free. Slow, steady growth beat fast, fragile growth in this case.

Equity is not always wrong — but be selective

Some businesses genuinely need the scale that only large capital infusions can provide. A capital-intensive business like a chip fabrication plant cannot bootstrap its way to relevance. The point is not to avoid investors altogether. The point is to be selective about which investors you bring into the business.

Until you find an investor who understands your timeline and shares your vision, a loan may serve you better. A loan has a fixed cost and a fixed schedule that you control. An equity investor has an open-ended claim on your company and an exit clock you do not control.

Treat funding rounds not as milestones to celebrate, but as partnership decisions that deserve the same scrutiny as a marriage.

You are choosing someone who will have a say in your company for years. Choose based on alignment, not just on the size of the check.

One simple test

My years of studying these companies taught me one simple test. Ask whether the money coming in understands the oxygen it is providing. If it does, the partnership has a real chance of working. If it does not, prepare for the ventilator to get pulled at the worst possible time.